Literature DB >> 2204409

Methotrexate-induced leukoencephalopathy is treatable with high-dose folinic acid: a case report and analysis of the literature.

I J Cohen1, B Stark, C Kaplinsky, R Weitz, S Matz, P Lerman, E Rakowsky, R Vogel, R Zaizov.   

Abstract

An episode of leukoencephalopathy is reported in a 13-year-old girl who, after standard radiotherapy for a posterior fossa medulloblastoma, received 8 treatments with a protocol containing a 4-hour infusion of 500 mg/m2 methotrexate and 12 mg intrathecal methotrexate. The leukoencephalopathy, documented clinically and by CT and EEG, cleared after 2350 mg of leucovorin (citrovorum factor, folinic acid) was given in addition to the 135 mg given as part of the therapy. A review of the literature suggests that leukoencephalopathy may be prevented by high doses of leucovorin and can be treated by high doses, if lower doses were used initially. When high dose leucovorin was not used, residual neurological damage is not unusual.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2204409     DOI: 10.3109/08880019009034321

Source DB:  PubMed          Journal:  Pediatr Hematol Oncol        ISSN: 0888-0018            Impact factor:   1.969


  3 in total

1.  Acute pseudobulbar palsy due to methotrexate with rapid response to intravenous immunoglobulin.

Authors:  P Kinirons; A Fortune; H Enright; R P J Murphy
Journal:  J Neurol       Date:  2005-11       Impact factor: 4.849

2.  Methotrexate Induced Acute Encephalopathy-Occurrence on Re-challenge and Response to Aminophylline.

Authors:  Prasanth Ganesan; Peush Bajpai; Akash Shah; Parthasarathy Saikrishnan; Tenali Gnana Sagar
Journal:  Indian J Hematol Blood Transfus       Date:  2013-06-12       Impact factor: 0.900

3.  Suicide attempt induced by drug-induced leukoencephalopathy: A case report.

Authors:  Ryo Maehara; Yasushi Kawamata; Motoshi Ichikawa; Kinuko Mitani; Norio Yasui-Furukori; Kazutaka Shimoda
Journal:  Neuropsychopharmacol Rep       Date:  2021-10-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.